Denver, CO

Colorado Allergy and Asthma Centers, PC

Rhinitis

Allergic Rhinitis

Asthma

Seasonal Allergic Rhinitis

Exercise-Induced Asthma

Cough

Bronchial Spasm

Perennial Allergic Rhinitis

Fluticasone Propionate

PF-03715455

Azelastine

albuterol

Albuterol

Ciclesonide

BLU-5937

azelastine hydrochloride

Azelastine hydrochloride

Meda Pharmaceuticals

Teva Pharmaceuticals

Bellus Health

Novartis

Pfizer

Sumitomo Pharma

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)

Colorado Allergy and Asthma Centers, PC | Denver, CO

Site insights

Work at this site?

Active trials

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)

Trial sponsors